Literature DB >> 21719456

Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure.

Fabrice Ivanes1, Sophie Susen, Frédéric Mouquet, Pascal Pigny, François Cuilleret, Karine Sautière, Jean-Philippe Collet, Farzin Beygui, Bernadette Hennache, Pierre Vladimir Ennezat, Françis Juthier, Florence Richard, Jean Dallongeville, Marieke A Hillaert, Pieter A Doevendans, Brigitte Jude, Michel Bertrand, Gilles Montalescot, Eric Van Belle.   

Abstract

BACKGROUND: Recent studies have demonstrated that aldosterone levels measured in patients with heart failure or acute myocardial infarction (MI) are associated with long-term mortality, but the association with aldosterone levels in patients with coronary artery disease (CAD) outside these specific settings remains unknown. In addition, no clear mechanism has been elucidated to explain these observations. The present study was designed to evaluate the relationship between the level of aldosterone and the risk of death and acute ischaemic events in CAD patients with a preserved left ventricular (LV) function and no acute MI. METHODS AND
RESULTS: In 799 consecutive CAD patients referred for elective coronary angioplasty measurements were obtained before the procedure for: aldosterone (median = 25 pg/mL), brain natriuretic peptide (BNP) (median = 35 pg/mL), hsC-reactive protein (median = 4.17 mg/L), and left ventricular ejection fraction (mean = 58%). Patients with acute MI or coronary syndrome (ACS) who required urgent revascularization were not included in the study. The primary endpoint, cardiovascular death, occurred in 41 patients during a median follow-up period of 14.9 months. Secondary endpoints-total mortality, acute ischaemic events (acute MI or ischaemic stroke), and the composite of death and acute ischaemic events-were observed in 52, 54, and 94 patients, respectively. Plasma aldosterone was found to be related to BMI, hypertension and NYHA class, and inversely related to age, creatinine clearance, and use of beta-blockers. Multivariate Cox model analysis demonstrated that aldosterone was independently associated with cardiovascular mortality (P = 0.001), total mortality (P = 0.001), acute ischaemic events (P = 0.01), and the composite of death and acute ischaemic events (P = 0.004). Reclassification analysis, using integrated discrimination improvement (IDI) and net reclassification improvement (NRI), demonstrated incremental predictive value of aldosterone (P < 0.0001).
CONCLUSION: Our results demonstrate that, in patients with CAD but without heart failure or acute MI, the level of aldosterone is strongly and independently associated with mortality and the occurrence of acute ischaemic events.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21719456     DOI: 10.1093/eurheartj/ehr176

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  46 in total

1.  Essential role of ICAM-1 in aldosterone-induced atherosclerosis.

Authors:  Vincenzo Marzolla; Andrea Armani; Caterina Mammi; Mary E Moss; Vittoria Pagliarini; Laura Pontecorvo; Antonella Antelmi; Andrea Fabbri; Giuseppe Rosano; Iris Z Jaffe; Massimiliano Caprio
Journal:  Int J Cardiol       Date:  2017-01-05       Impact factor: 4.164

Review 2.  Aldosterone in heart disease.

Authors:  Anastasia S Mihailidou
Journal:  Curr Hypertens Rep       Date:  2012-04       Impact factor: 5.369

Review 3.  New insights into insulin action and resistance in the vasculature.

Authors:  Camila Manrique; Guido Lastra; James R Sowers
Journal:  Ann N Y Acad Sci       Date:  2014-03-20       Impact factor: 5.691

4.  Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial).

Authors:  Muthiah Vaduganathan; Alessandra Dei Cas; Robert J Mentz; Stephen J Greene; Sadiya Khan; Haris P Subacius; Ovidiu Chioncel; Aldo P Maggioni; Marvin A Konstam; Michele Senni; Gregg C Fonarow; Javed Butler; Mihai Gheorghiade
Journal:  Am J Cardiol       Date:  2014-06-24       Impact factor: 2.778

Review 5.  Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease.

Authors:  Nicholas C Bene; Pilar Alcaide; Henry H Wortis; Iris Z Jaffe
Journal:  Steroids       Date:  2014-04-21       Impact factor: 2.668

6.  Mineralocorticoid receptor throughout the vessel: a key to vascular dysfunction in obesity.

Authors:  Luminita H Pojoga; Rene Baudrand; Gail K Adler
Journal:  Eur Heart J       Date:  2013-05-10       Impact factor: 29.983

Review 7.  Direct role for smooth muscle cell mineralocorticoid receptors in vascular remodeling: novel mechanisms and clinical implications.

Authors:  Jenny B Koenig; Iris Z Jaffe
Journal:  Curr Hypertens Rep       Date:  2014-05       Impact factor: 5.369

8.  Aldosterone predicts major adverse cardiovascular events in patients with acute myocardial infarction.

Authors:  Matthew Fomonyuy Yuyun; Sandeep K Jutla; Paulene A Quinn; Leong L Ng
Journal:  Heart Asia       Date:  2012-08-24

9.  Lipophilic Statins and Aldosterone Secretion: A Bridge Too Far?

Authors:  Charlotte Andersson; Ramachandran S Vasan
Journal:  Circulation       Date:  2015-10-02       Impact factor: 29.690

Review 10.  Mineralocorticoid receptors in vascular disease: connecting molecular pathways to clinical implications.

Authors:  Adam P McGraw; Amy McCurley; Ioana R Preston; Iris Z Jaffe
Journal:  Curr Atheroscler Rep       Date:  2013-07       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.